ENDRA Life Sciences

NDRA

시가총액 US$711만

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update. Second Quarter 2026 and Recent Highlights On June 25, 2026, ENDRA entered into a definitive merger agreement with ASP Isotopes Inc. (NASDAQ: ASPI), Noble Africa LLC (“Noble Africa”) , R.

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) (“ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of our business units appear at an inflection point and are expected to make substantial contributions to achieving profitability in the near term: During 1H 2026, our global PET Labs group demonstrated organic revenue growth of over 50% as compared to 1H 2025.

Noble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNG Learn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar featuring Noble Africa, a wholly owned subsidiary of ASP Isotopes and the holding company for Renergen Limited, on Tuesday, July 21, 2026, at 4:15 p.m. ET. The webinar will highlight Noble Africa's proposed merger (the "Proposed Merger" and, together with the related transactions, the "Proposed Transactions") with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company trading under the ticker symbol "NOBA.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ENDRA Life Sciences Inc. (NASDAQ: NDRA) with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.Halper Sadeh encourages ENDRA shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or zhalp.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an ex.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluat.

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that its Board of Directors has initiated a process to evaluate a range of strategic alternatives aimed at maximizing shareholder value. As a part of this process, the Board will evaluate a range of potential alternatives, including, but not limited to strategic in.

ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its regulatory and commercial outlook.